Bridgefront Capital’s Q32 Bio QTTB Stock Holding History

Bridgefront Capital’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-707	Closed	-$120K	–	954
2021 Q1	$120K	Sell	707 -179	-20%	-$37.7K	0.04%	614
2020 Q4	$180K	Buy	+886	New	+$171K	0.06%	533

Other funds holding QTTB

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Bridgefront Capital's QTTB Position: Q2 2021 in Review

Bridgefront Capital sold out of Q32 Bio (QTTB) in Q2 2021, closing a stake of 707 shares — an estimated $120K sold.

Bridgefront Capital first reported a position in QTTB in Q4 2020 and held it in 2 quarters. The position peaked at $180K in Q4 2020. 118 funds tracked by Wall St. Rank hold QTTB as of Q2 2021.

Bridgefront Capital reported no remaining Q32 Bio position as of Q2 2021 after selling out during the quarter.
Bridgefront Capital sold 707 Q32 Bio shares in Q2 2021, an estimated $120K.
Bridgefront Capital first reported a position in Q32 Bio in Q4 2020 and held it in 2 quarters.
Bridgefront Capital's Q32 Bio position peaked at $180K in Q4 2020.
118 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.